Nebokitug(抗CCL24单抗)治疗原发性硬化性胆管炎的2期研究
SPRING研究为随机双盲安慰剂对照2期试验,76例大胆管型原发性硬化性胆管炎患者接受Nebokitug 10 mg/kg、20 mg/kg或安慰剂每3周静脉给药15周。主要终点安全耐受性组间相似,总人群肝酶、ELF和LSM无显著变化,但中/晚期纤维化亚组LSM显著下降。开放扩展至48周耐受良好。
要点
- Nebokitug在原发性硬化性胆管炎患者中安全耐受,不良事件频率与严重程度与安慰剂相似。
- 总治疗人群15周肝血液检查、ELF评分和LSM较基线无显著变化。
- 中/晚期纤维化亚组(n=35)接受Nebokitug后LSM显著降低。
核心结论
- Nebokitug在原发性硬化性胆管炎患者中耐受良好,最长治疗48周未发现新安全信号。
- 总人群15周肝血液检查、ELF评分和LSM无显著变化,但中/晚期纤维化亚组LSM显著降低。
研究设计与样本
- SPRING为随机、双盲、安慰剂对照2期研究,纳入大胆管型原发性硬化性胆管炎患者。
- 患者随机接受静脉Nebokitug 10 mg/kg、20 mg/kg或安慰剂,每3周一次,共15周。
- 共76例患者入组并至少接受一剂Nebokitug(n=56)或安慰剂(n=20)。
- 完成15周双盲期的合格患者进入开放扩展研究,接受Nebokitug总计48周。
主要发现
- 治疗中出现的不良事件频率和严重程度在Nebokitug组与安慰剂组间相似。
- 总治疗人群从基线至第15周肝血液检查、ELF评分和LSM无显著变化。
- 预设的中/晚期纤维化亚组(n=35)中,Nebokitug治疗患者LSM显著降低。
- 54例合格患者中50例进入开放扩展研究,Nebokitug持续耐受良好,未观察到新安全信号。
关键数值与推荐
- 主要终点为安全性和耐受性。
- 次要终点包括第15周肝血液检查、增强肝纤维化(ELF)评分和肝脏硬度测量(LSM)较基线的变化。
- 在预设的中/晚期纤维化亚组中探索生物学活性。
临床怎么用
- Nebokitug可能为原发性硬化性胆管炎伴中/晚期纤维化患者提供抗纤维化获益,需进一步验证。
- 治疗期间需监测不良事件,当前数据支持其安全耐受性。
局限性
- 为2期研究,样本量有限(76例),结果需更大规模试验确认。
- 总人群主要终点未显示显著生物标志物改善,仅亚组分析提示LSM降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Nebokitug (CM-101) is an antichemokine (C-C motif) ligand 24 monoclonal antibody with anti-inflammatory and antifibrotic properties. This phase 2 study evaluated the safety, tolerability, and biological activity of nebokitug in patients with primary sclerosing cholangitis (PSC). METHODS: SPRING was a randomized, double-blind (DB), placebo-controlled phase 2 study in which patients with large duct PSC were randomized to receive IV nebokitug 10 mg/kg, 20 mg/kg, or placebo every 3 weeks for 15 weeks. The primary end point was safety and tolerability. Secondary end points included change from baseline to week 15 in liver blood tests, enhanced liver fibrosis (ELF) score, and liver stiffness measurements (LSM). Biological activity was explored in a prespecified subgroup with moderate/advanced fibrosis. Eligible patients who completed the 15-week DB period entered the open-label extension study to receive nebokitug for a total of 48 weeks. RESULTS: A total of 76 patients were enrolled and received at least 1 dose of nebokitug (n = 56) or placebo (n = 20). Frequency and severity of treatment-emergent adverse events were similar between the groups. No significant changes in liver tests, ELF scores, and LSM from baseline to week 15 were observed in the total treatment population. However, in the prespecified subgroup of patients with moderate/advanced fibrosis (n = 35), patients treated with nebokitug showed a significant reduction in LSM. Of the 54 patients eligible to participate, 50 enrolled in the OLE. Nebokitug continued to be well tolerated, and no new safety signal was observed. DISCUSSION: Nebokitug was well tolerated up to 48 weeks of treatment and demonstrated numerical biomarker improvements in patients with PSC, particularly in those with moderate/advanced fibrosis.
引用
- Bowlus CL, Thorburn D, Barclay ST, et al. Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 Study. Am J Gastroenterol. 2025. PMID: 41257532. doi:10.14309/ajg.0000000000003853
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。